Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Everest Medicines Ltd. ( (HK:1952) ) is now available.
Everest Medicines Ltd. announced a significant increase in shareholding by its directors and a substantial shareholder, CBC Group. This move, involving a purchase of shares worth over HK$38 million, reflects strong confidence in the company’s future prospects and long-term development, potentially impacting its market positioning positively.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Ltd. is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in the fields of oncology, autoimmune disorders, cardio-renal diseases, and infectious diseases. The company is committed to addressing unmet medical needs in the Asian market.
Average Trading Volume: 3,431,380
Technical Sentiment Signal: Hold
Current Market Cap: HK$15.85B
For detailed information about 1952 stock, go to TipRanks’ Stock Analysis page.